Mantle Cell Lymphoma | Specialty

Dr. Fenske Discusses Disease Progression on Ibrutinib in MCL

April 21st 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses his recommendations for oncologists treating patients with mantle cell lymphoma (MCL) who are progressing on ibrutinib (Imbruvica).

Dr. Shah on Challenges With Developing MCL Clinical Trials

April 19th 2019

Bijal D. Shah, MD, associate member, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses challenges with developing mantle cell lymphoma clinical trials.

Dr. Goy on Treatment Considerations in MCL

April 18th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment considerations in mantle cell lymphoma.

Clinical Factors in MCL Successful in Guiding Watch-and-Wait Strategy

April 18th 2019

Although biological criteria carry prognostic value in mantle cell lymphoma, initial observation based solely on clinical criteria was found to be an effective management strategy that did not compromise patient outcomes.

Dr. LaCasce on Key Advances in the MCL Paradigm

April 18th 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses key advances made in the mantle cell lymphoma (MCL) paradigm.

MCL Armamentarium Expands, But Quest Continues for Curative Approaches

April 17th 2019

Ann S. LaCasce, MD, MMSc, highlights the therapeutic progress in the treatment of patients with mantle cell lymphoma , key remaining challenges, and where future research is headed.

Dr. Shah on Overcoming Resistance to BTK Inhibitors in MCL

April 17th 2019

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in the treatment of mantle cell lymphoma.

Dr. Goy on Treatment Options for Patients With MCL

April 11th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment options for patients with mantle cell lymphoma (MCL).

Dr. Lossos on Research Questions in MCL

April 5th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses research questions in the field of mantle cell lymphoma (MCL).

Dr. Goy on Future Treatment Approaches in MCL

April 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses future treatment approaches in patients with mantle cell lymphoma.

Dr. Patel on Emerging Therapeutic Strategies in MCL

March 20th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Despite Progress in Follicular Lymphoma and MCL, Critical Questions Remain

March 20th 2019

Izidore S. Lossos, MD, discusses the current pillars of care and barriers in the treatment of patients with early-stage and advanced follicular lymphoma, as well as mantle cell lymphoma.

Dr. Lossos on Treatment Approaches in MCL

March 19th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses treatment approaches for patients with mantle cell lymphoma (MCL).

Stratification Schemes Guide Treatment Decisions in MCL

March 19th 2019

Andre Goy, MD, MS, shares insight on the stratification of patients with mantle cell lymphoma and other molecular markers that are being applied towards optimal treatment decisions in this disease.

Dr. Goy on Molecular Features of Mantle Cell Lymphoma

March 15th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the molecular features of mantle cell lymphoma (MCL).

Dr. Patel Discusses Zanubrutinib in MCL

March 11th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Goy Discusses Challenges in Treatment of MCL

March 6th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses challenges in the treatment of patients with mantle cell lymphoma.

Using BTK Inhibitors in Community Practice

March 4th 2019

BTK Combination Strategies for B-Cell Malignancies

March 4th 2019

BTK Inhibitors in Chronic Lymphocytic Leukemia

March 4th 2019